MELISSA FLEMISTER: Open Payments
NPI 1205275120 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$738 in 25 payments from 13 companies in 2025. Trend: 2023 $653 · 2024 $602 · 2025 $738
Food & beverage: $738
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $215 |
| Novo Nordisk Inc | 5 | $169 |
| PFIZER INC. | 4 | $92 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| Lilly USA, LLC | 2 | $35 |
| UCB, Inc. | 1 | $31 |
| ABBVIE INC. | 1 | $24 |
| Neurelis, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
Products named: FARXIGA, Ozempic, PREVNAR 20, Rybelsus, JARDIANCE, Briviact, AIRSUPRA, VRAYLAR.
Industry payments across LA — which companies pay providers there.
